Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International (NASDAQ: DYAI) reported a 40.8% revenue increase in Q1 2022, reaching approximately $534,000. The company secured a new collaboration with a global food ingredients firm and a license deal with Phibro for animal vaccines. Positive developments include advancing a first-in-human clinical trial application for the DYAI-100 COVID-19 vaccine in South Africa, while a C1-produced antibody showed efficacy against Omicron variants. Cash and investments stood at $17.5 million as of March 31, 2022, against a net loss of approximately $2.49 million.

Dyadic International, Inc. (NASDAQ: DYAI) has entered into a Joint Development Agreement with a Global Food Ingredients Company to produce animal-free ingredient products. The project is fully funded with €3.6 million. Dyadic will develop proprietary production cell lines and can earn success and commercialization fees, along with royalties on sales. This partnership illustrates Dyadic's capacity to leverage its C1 protein production platform beyond biopharmaceuticals, tapping into emerging markets and enhancing its value in biomanufacturing.

Dyadic International announced positive results from a toxicology study of its COVID-19 vaccine candidate, DYAI-100, published in Toxicologic Pathology. The study revealed an excellent safety profile and strong immunogenic responses in animal models. The findings support Dyadic’s upcoming First-In-Human clinical trial and validate its C1-cell protein production platform, which aims to lower biopharmaceutical production costs. This marks Dyadic's third peer-reviewed publication in 2022 regarding the efficacy and safety of its products.

Dyadic International, Inc. (NASDAQ: DYAI) announced its upcoming financial results report for Q1 2022, scheduled for May 12, 2022, at 5:00 p.m. ET. The company specializes in using its proprietary C1-cell protein production platform to enhance the development and production of biologic drugs and vaccines at lower costs. The conference call will discuss financial performance and future strategies, accessible via specific dial-in numbers or a webcast link. Dyadic aims to leverage its C1 technology to improve access to biologics and save lives.

Dyadic International, Inc. (NASDAQ: DYAI) announced that its licensee, Epygen Biotech, received funding from India's Department of Biotechnology to support Phase 1 and 2 clinical trials of a COVID-19 vaccine using Dyadic's C1 protein production platform. Epygen aims to develop a low-cost vaccine, anticipated to be priced around $2 per dose, targeting the production of 100 million doses annually. Additionally, Epygen plans to raise $26 million for Phase 3 trials to enhance production capacity and expedite vaccine availability.

Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced its participation in key scientific meetings in April 2022. The company will present its proprietary C1-cell protein production platform aimed at enhancing biologic vaccine and drug development during the Microbial Engineering II conference in Portugal and the World Vaccine Congress in Washington, DC. Presentations will cover topics including therapeutic protein production and innovative vaccine manufacturing solutions, showcasing how C1 can reduce costs and improve efficiency in biopharmaceuticals.

Dyadic International (NASDAQ: DYAI) announced substantial developments, including a collaboration with Janssen for therapeutic proteins, securing a $690,000 NIIMBL grant, and a license agreement with Phibro Animal Health for vaccines. The company anticipates advancing its DYAI-100 COVID-19 vaccine toward human trials. Financial highlights reveal a 50% increase in R&D revenue to $2.4 million for 2021, although the net loss rose to approximately $13.1 million. Cash and investments stood at $20.4 million, down from $29.2 million in 2020.

Dyadic International, a biotechnology firm (NASDAQ: DYAI), announced it will report its 2021 financial results and host a corporate update conference call on March 29, 2022. The company is focused on its proprietary C1-cell protein platform, which aims to lower production costs and enhance biologic vaccine and drug development. The conference will be accessible via dial-in or webcast, providing shareholders an opportunity to stay informed about the company's operations and future prospects.

Dyadic International and Phibro Animal Health have entered an exclusive license agreement to utilize Dyadic's C1-cell protein production platform for developing a poultry vaccine targeting a specific disease. This partnership follows successful proof of concept animal trials. The agreement allows Phibro to produce targeted antigens for vaccine commercialization. Both companies plan to continue their collaboration to develop additional animal vaccine candidates, thereby enhancing the efficiency of vaccine production.